Annual Accounts Receivable
$821.00 K
-$6.61 M-88.96%
December 31, 2023
Summary
- As of February 7, 2025, ADAP annual accounts receivable is $821.00 thousand, with the most recent change of -$6.61 million (-88.96%) on December 31, 2023.
- During the last 3 years, ADAP annual accounts receivable has risen by +$682.00 thousand (+490.65%).
- ADAP annual accounts receivable is now -88.96% below its all-time high of $7.43 million, reached on December 31, 2022.
Performance
ADAP Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$12.50 M
+$10.16 M+435.33%
September 30, 2024
Summary
- As of February 7, 2025, ADAP quarterly accounts receivable is $12.50 million, with the most recent change of +$10.16 million (+435.33%) on September 30, 2024.
- Over the past year, ADAP quarterly accounts receivable has increased by +$4.10 million (+48.74%).
- ADAP quarterly accounts receivable is now at all-time high.
Performance
ADAP Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
ADAP Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -89.0% | +48.7% |
| 3 y3 years | +490.6% | +661.7% |
| 5 y5 years | +327.6% | +100.0% |
ADAP Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -89.0% | +9.2% | at high | +1562.2% |
| 5 y | 5-year | -89.0% | -100.0% | at high | -100.0% |
| alltime | all time | -89.0% | -100.0% | at high | -100.0% |
Adaptimmune Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $12.50 M(+435.3%) |
| Jun 2024 | - | $2.33 M(-72.2%) |
| Mar 2024 | - | $8.40 M(+923.6%) |
| Dec 2023 | $821.00 K(-89.0%) | $821.00 K(+4.1%) |
| Sep 2023 | - | $789.00 K(-73.4%) |
| Jun 2023 | - | $2.97 M(+73.2%) |
| Mar 2023 | - | $1.72 M(-76.9%) |
| Dec 2022 | $7.43 M(+888.7%) | $7.43 M(+319.1%) |
| Sep 2022 | - | $1.77 M(-25.5%) |
| Jun 2022 | - | $2.38 M(+30.4%) |
| Mar 2022 | - | $1.83 M(+142.8%) |
| Dec 2021 | $752.00 K(+441.0%) | $752.00 K(-54.2%) |
| Sep 2021 | - | $1.64 M(-24.0%) |
| Jun 2021 | - | $2.16 M(+1452.5%) |
| Dec 2020 | $139.00 K(>+9900.0%) | $139.00 K(>+9900.0%) |
| Dec 2019 | $0.00 | $0.00(0.0%) |
| Sep 2019 | - | $0.00(-100.0%) |
| Jun 2019 | - | $3.81 M(>+9900.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2019 | - | $0.00(-100.0%) |
| Dec 2018 | $192.00 K(-6.8%) | $192.00 K(-90.5%) |
| Sep 2018 | - | $2.03 M(>+9900.0%) |
| Jun 2018 | - | $0.00(-100.0%) |
| Mar 2018 | - | $5.05 M(+2352.4%) |
| Dec 2017 | $206.00 K(-86.1%) | $206.00 K(-94.9%) |
| Sep 2017 | - | $4.06 M(+189.0%) |
| Jun 2017 | - | $1.41 M(+1214.0%) |
| Mar 2017 | - | $107.00 K(-92.8%) |
| Dec 2016 | $1.48 M(+98.9%) | $1.48 M(>+9900.0%) |
| Jun 2016 | - | $0.00(-100.0%) |
| Mar 2016 | - | $1000.00(-100.0%) |
| Dec 2015 | $744.00 K(>+9900.0%) | - |
| Sep 2015 | - | $7.76 M(+25.3%) |
| Jun 2015 | $4000.00(-85.3%) | - |
| Dec 2014 | - | $6.19 M(>+9900.0%) |
| Jun 2014 | $27.30 K(+1720.0%) | $27.30 K |
| Jun 2013 | $1500.00(-96.0%) | - |
| Jun 2012 | $37.70 K | - |
FAQ
- What is Adaptimmune Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics annual accounts receivable year-on-year change?
- What is Adaptimmune Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics quarterly accounts receivable year-on-year change?
What is Adaptimmune Therapeutics annual accounts receivable?
The current annual accounts receivable of ADAP is $821.00 K
What is the all time high annual accounts receivable for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high annual accounts receivable is $7.43 M
What is Adaptimmune Therapeutics annual accounts receivable year-on-year change?
Over the past year, ADAP annual accounts receivable has changed by -$6.61 M (-88.96%)
What is Adaptimmune Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of ADAP is $12.50 M
What is the all time high quarterly accounts receivable for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high quarterly accounts receivable is $12.50 M
What is Adaptimmune Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, ADAP quarterly accounts receivable has changed by +$4.10 M (+48.74%)